Drug intelligence / Profile preview

varicella vaccine live

Development stage: Phase 4
Lead developer: Sinovac Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Sinovac's varicella vaccine is a live attenuated vaccine indicated for the active immunization against varicella (chickenpox) in healthy individuals, typically starting from 12 months of age. Developed by Sinovac (Dalian) Vaccine Technology Co., Ltd., the vaccine is produced using the proprietary SV-1 human diploid cell line. A key feature of this formulation is that it is gelatin-free and blood albumin-free, which helps reduce the incidence of allergic reactions. The vaccine has been evaluated in multiple clinical trials for safety, immunogenicity, and protective efficacy, and it is approved for marketing in China.

Other names: Sinovac varicella vaccinelive attenuated varicella vaccinevaricella virus vaccine livevaricella virus live attenuated vaccine

Beyond the preview

Go deeper on varicella vaccine live.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on varicella vaccine live.

Explore the full profile